Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phased telitacicept in IgA nephropathy
ChiCTR2400092894Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in IgA nephropathy (IgAN), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: 24-hour urine protein. Started Nov 2024; status: recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2400092894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092894.